Document:

Exhibit 4.2(t)

 

“CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS
DOCUMENT HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION.  CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.”

 

PATENT AND TECHNOLOGY LICENSE AGREEMENT

 

This twenty-eight (28) page AGREEMENT
(“AGREEMENT”) is made on this seventh day of February, 2005, by and between THE
BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an
agency of the State of Texas, whose address is 201 West 7th Street, Austin,
Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER
(“UTMDACC”), a component institution of SYSTEM, and CHEMGENEX PHARMACEUTICALS
LIMITED, an Australian corporation having its principal place of business
located at 1 Pigdons Road, Waurn Ponds, Victoria, 3217, AUSTRALIA (“LICENSEE”).

 

TABLE OF CONTENTS

 

	
  RECITALS

  	
   

  
	
  I.
  EFFECTIVE DATE

  	
   

  
	
  II.
  DEFINITIONS

  	
   

  
	
  III. LICENSE

  	
   

  
	
  IV.
  CONSIDERATION, PAYMENTS AND REPORTS

  	
   

  
	
  V. SPONSORED RESEARCH
  AND OPTION

  	
   

  
	
  VI. PATENTS AND INVENTIONS

  	
   

  
	
  VII. INFRINGEMENT BY
  THIRD PARTIES

  	
   

  
	
  VIII.
  PATENT MARKING

  	
   

  
	
  IX. INDEMNIFICATION
  AND INSURANCE

  	
   

  
	
  X. USE OF BOARD AND
  UTMDACC’S NAME

  	
   

  
	
  XI.
  CONFIDENTIAL INFORMATION AND PUBLICATION

  	
   

  
	
  XII.
  ASSIGNMENT

  	
   

  
	
  XIII. TERM AND TERMINATION

  	
   

  
	
  XIV. WARRANTY:
  SUPERIOR-RIGHTS

  	
   

  
	
  XV. GENERAL

  	
   

  
	
  SIGNATURES

  	
   

  

 

1

 

RECITALS

 

A.                                   BOARD
owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED SUBJECT
MATTER developed at UTMDACC.

 

B.                                     BOARD,
through UTMDACC, desires to have the LICENSED SUBJECT MATTER developed in the
LICENSED FIELD and used for the benefit of LICENSEE, BOARD, SYSTEM, UTMDACC,
the inventor(s), and the public as outlined in BOARD’s Intellectual Property
Policy.

 

C.                                     LICENSEE
wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER.

 

NOW, THEREFORE, in consideration of the mutual
covenants and promises herein contained, the parties agree as follows:

 

I.              EFFECTIVE DATE

 

1.1                                 This
AGREEMENT is effective as of the date written above (“EFFECTIVE DATE”).

 

II.            DEFINITIONS

 

As used in this
AGREEMENT, the following terms have the meanings indicated:

 

2.1                                 AFFILIATE
means any business entity more than fifty percent (50%) owned by LICENSEE, any
business entity which owns more than fifty percent (50%) of LICENSEE, or any
business entity that is more than fifty percent (50%) owned by a business
entity that owns more than fifty percent (50%) of LICENSEE.

 

2.2                                 LICENSED FIELD means all fields of use.

 

2.3                                 LICENSED PRODUCTS means any
product or service comprising LICENSED SUBJECT MATTER sold by LICENSEE or a
third party pursuant to the license granted to LICENSEE under this AGREEMENT.

 

2

 

2.4                                 LICENSED SUBJECT MATTER means
inventions and discoveries covered by PATENT RIGHTS or TECHNOLOGY RIGHTS within
LICENSED FIELD.

 

2.5                                 LICENSED TERRITORY means
worldwide.

 

2.6                                 MARKETING APPROVAL means the
approvals, licenses, registrations or authorizations necessary to market and
sell a LICENSED PRODUCT in a country.

 

2.7                                 NDA means a New Drug
Application or Biologics License Application filed with the United States Food
and Drug Administration for MARKETING APPROVAL, or an equivalent application
filed with any equivalent agency or governmental authority outside of the
United States.

 

2.8                                 NET SALES means the gross
revenues received by LICENSEE, its sublicensees, its affiliates, its assignees,
its distributors, or any other third party selling LICENSED PRODUCTS pursuant
to the license granted under this AGREEMENT, from a SALE less sales discounts
actually granted, sales and/or use taxes actually paid, import and/or export
duties actually paid, outbound transportation actually prepaid or allowed, and
amounts actually allowed or credited due to returns (not exceeding the original
billing or invoice amount), all as recorded by LICENSEE in LICENSEE’s official
books and records in accordance with generally accepted accounting practices
and consistent with LICENSEE’s published financial statements and/or regulatory
filings with the United States Securities and Exchange Commission.

 

2.9                                 PATENT RIGHTS means BOARD’s
rights in information or discoveries described in the claims of United States
Patent No. 5,434,256 as specified and limited in Exhibit I attached
hereto. PATENT RIGHTS do not include the complex of Claim 1, compositions
comprising the complex of Claim 1, or methods of making or using the complex of
Claim 1, as set forth in United States Patent No. 5,434,256.

 

3

 

2.10                           PHASE I CLINICAL TRIAL means a
clinical trial for the initial introduction of LICENSED PRODUCT into humans,
designed to determine the metabolic and pharmacologic actions of the LICENSED
PRODUCT in humans, the side effects associated with increasing doses, and, if
possible, to gain early evidence on effectiveness..

 

2.11                           PHASE II CLINICAL TRIAL means
a human clinical trial prospectively designed to provide evidence of the
efficacy of a LICENSED PRODUCT in one or more clinical indications and expanded
evidence of the safety of LICENSED PRODUCT, as well as provide an indication of
the dosage regimen required, in a manner sufficient (if successful) to initiate
a PHASE III CLINICAL TRIAL.

 

2.12                           PHASE III CLINICAL TRIAL means
a large-scale human clinical trial prospectively designed to demonstrate with
statistical significance whether a LICENSED PRODUCT is safe and effective for
use in a particular indication and a particular dosage regimen in a manner
sufficient (if successful) to file for MARKETING APPROVAL.

 

2.13                           SALE or SOLD means the
transfer or disposition of a LICENSED PRODUCT for value to a party other than
LICENSEE or AFFILIATE.

 

2.14                           TECHNOLOGY RIGHTS means BOARD’s
rights in any technical information, know-how, processes, procedures,
compositions, devices, methods, formulae, protocols, techniques, software,
designs, drawings or data created by the inventor(s) listed in Exhibit I
at UTMDACC before the EFFECTIVE DATE, which are not claimed in PATENT RIGHTS
but that are necessary for practicing PATENT RIGHTS.  TECHNOLOGY RIGHTS do not include the complex
of Claim 1, compositions comprising the complex of Claim 1, or methods of
making or using the complex of Claim 1, as set forth in United States Patent No. 5,434,256.

 

4

 

III.           LICENSE

 

3.1                                 BOARD,
through UTMDACC, hereby grants to LICENSEE a royalty-bearing, exclusive license
under LICENSED SUBJECT MATTER to manufacture, have manufactured, use, import,
offer to sell and/or sell LICENSED PRODUCTS within LICENSED TERRITORY for use
within LICENSED FIELD.  This grant is subject to Sections
14.2 and 14.3 hereinbelow, the payment by LICENSEE to UTMDACC of all
consideration as provided herein, the timely payment of all amounts due under
any related sponsored research agreement between UTMDACC and LICENSEE in effect
during this AGREEMENT, and is further subject to the following rights retained
by BOARD and UTMDACC to:

 

(a)                                  Publish
the general scientific findings from research related to LICENSED SUBJECT
MATTER, subject to the terms of Article XI–Confidential Information and
Publication; and

 

(b)                                 Use
LICENSED SUBJECT MATTER for research, teaching, patient care, and other
educationally-related purposes.

 

3.2                                 LICENSEE
may extend the license granted herein to any AFFILIATE provided that the
AFFILIATE consents in writing to be bound by this AGREEMENT to the same extent
as LICENSEE.  LICENSEE agrees to deliver
such contract to UTMDACC within thirty (30) calendar days following execution
thereof.

 

3.3                                 LICENSEE
may grant sublicenses under LICENSED SUBJECT MATTER consistent with the terms
of this AGREEMENT provided that LICENSEE is responsible for its sublicensees
relevant to this AGREEMENT, and for diligently collecting all amounts due
LICENSEE from sublicensees. If a sublicensee pursuant hereto becomes bankrupt,
insolvent or is placed in the hands of a receiver or trustee, LICENSEE, to the
extent

 

5

 

allowed under applicable law and in a timely manner,
agrees to use its best reasonable efforts to collect all consideration owed to
LICENSEE and to have the sublicense agreement confirmed or rejected by a court
of proper jurisdiction.

 

3.4                                 LICENSEE
must deliver to UTMDACC a true and correct copy of each sublicense granted by
LICENSEE, and any modification or termination thereof, within thirty (30)
calendar days after execution, modification, or termination.

 

3.5                                 If
this AGREEMENT is terminated pursuant to Article XIII-Term and
Termination, BOARD and UTMDACC agree to accept as successors to LICENSEE,
existing sublicensees in good standing at the date of termination provided that
each such sublicensee consents in writing to be bound by all of the terms and
conditions of this AGREEMENT.

 

IV.           CONSIDERATION, PAYMENTS AND REPORTS

 

4.1                                 In
consideration of rights granted by BOARD to LICENSEE under this AGREEMENT,
LICENSEE agrees to pay UTMDACC the following:

 

(a)                                  All
out-of-pocket expenses incurred by UTMDACC in filing, prosecuting, enforcing
and maintaining PATENT RIGHTS, and all such future expenses incurred by
UTMDACC, for so long as, and in such countries as this AGREEMENT remains in
effect. UTMDACC will invoice LICENSEE within thirty (30) calendar days of the
EFFECTIVE DATE for expenses incurred as of that time and on a quarterly basis
thereafter.  The invoiced amounts will be
due and payable by LICENSEE within thirty (30) calendar days of invoice; and

 

(b)                                 A
nonrefundable license documentation fee in the amount of US$[*], which will be
paid by LICENSEE by: (i) delivering to UTMDACC US$[*] within thirty (30)
calendar days of execution of this AGREEMENT by all parties; and

 

6

 

(ii) delivering to
UTMDACC on behalf of BOARD US$[*] of fully paid ordinary shares of LICENSEE within
thirty (30) calendar days after the EFFECTIVE DATE.  The ordinary shares will be immediately
tradable on the Australian Stock Exchange, and the number of shares issuable
will be determined based on the volume weighted average closing price of
LICENSEE’s ordinary shares over the thirty (30) calendar day period immediately
preceding the day this AGREEMENT is executed by all parties.  The exchange rate from Australian to US
currency used for purposes of determining the number of shares will be
calculated based on the average closing rate during the same 30-day
period.  The board of directors of
LICENSEE will recommend approval of the issuance of the ordinary shares to
BOARD, and LICENSEE will use its best efforts to obtain shareholder approval
for the stock issuance.  In the event
that shareholder approval is not granted, LICENSEE agrees to pay UTMDACC within
thirty (30) calendar days after the EFFECTIVE DATE the cash value (in US
currency) of the number of ordinary shares issuable pursuant to this Section 4.1(b),
based upon the average closing price of LICENSEE’s ordinary shares and the
average exchange rate during the thirty (30) calendar day period immediately
preceding the EFFECTIVE DATE.  This
nonrefundable license documentation fee will not reduce the amount of any other
payment provided for in this ARTICLE IV; and

 

(c)                                  A
running royalty equal to [*] percent ([*]) of NET SALES, whether said NET SALES
are made by LICENSEE, its sublicensees, its affiliates, its assignees, its
distributors or any other third party selling LICENSED PRODUCTS pursuant to the
license granted under this AGREEMENT, provided that said running royalty may be
reduced to [*] half percent ([*]%) in territories where patents or

 

7

 

patent applications
directed to PATENT RIGHTS have expired, been abandoned, or have not issued; and

 

(d)                                 One
time milestone payments due and payable within [*] calendar days of achievement
of each of the following milestones:

 

(1)                                  $[*]
at the commencement of the first PHASE I CLINICAL TRIAL for any LICENSED
PRODUCT or an equivalent trial in any foreign jurisdiction, except as provided
in Section 4.1(d)(3) below. Commencement of a PHASE I CLINICAL TRIAL
or equivalent trial shall be deemed to occur upon the administration of a
LICENSED PRODUCT or placebo to the first individual enrolled in the PHASE I
CLINICAL TRIAL or equivalent trial;

 

(2)                                  $[*]
at the commencement of the first PHASE II CLINICAL TRIAL for any LICENSED
PRODUCT or an equivalent trial in any foreign jurisdiction, except as provided
in Section 4.1(d)(3) below. 
Commencement of a PHASE II CLINICAL TRIAL or equivalent trial shall be
deemed to occur upon the administration of a LICENSED PRODUCT or placebo to the
first individual enrolled in the PHASE II CLINICAL TRIAL or equivalent trial;

 

(3)                                  If
LICENSEE commences a combined PHASE I/PHASE II CLINICAL TRIAL for any LICENSED
PRODUCT or an equivalent trial in any foreign jurisdiction, milestone payments will
be made as provided for in 4.1(d)(1) and 4.1(d)(2) above based on
when the Phase I and Phase II portions of the study begin.

 

8

 

(4)                                  $[*]
at the commencement of the first PHASE III CLINICAL TRIAL for any LICENSED
PRODUCT or an equivalent trial in any foreign jurisdiction. Commencement of a
PHASE III CLINICAL TRIAL or equivalent trial shall be deemed to occur upon the
administration of a LICENSED PRODUCT or placebo to the first individual
enrolled in the PHASE III CLINICAL TRIAL or equivalent trial;

 

(5)                                  $[*]
at the first filing of an NDA with the Federal Drug Administration for any
LICENSED PRODUCT; and

 

(6)                                  $[*]
upon the first MARKETING APPROVAL of any LICENSED PRODUCT; and

 

(e)                                  The
following percentages of all consideration, other than research and development
money and royalties for NET SALES, received by LICENSEE from either (i) any
sublicensee, or (ii) any assignee pursuant to Section 12.1, including
but not limited to up-front payments, marketing, distribution, franchise,
option, license, or documentation fees, bonus, and milestone payments, and
equity securities, due and payable as follows:

 

(1)                                  For
the period beginning on the EFFECTIVE DATE up through and including the first
anniversary of the EFFECTIVE DATE – [*] percent ([*]%);

 

(2)                                  For
the period beginning the day after the first anniversary of the EFFECTIVE DATE
up through and including the second anniversary of the EFFECTIVE DATE – [*]
percent ([*]%); and

 

(3)                                  For
the period beginning the day after the second anniversary of the EFFECTIVE DATE
and thereafter – [*] percent ([*]%); and

 

9

 

(f)                                    In
case of the sale of all of LICENSEE’s assets to a third party, this AGREEMENT
may be assigned subject to the payment to UTMDACC of a $[*] license
documentation fee to UTMDACC prior to the assignment, whereupon the provisions
of Section 4.1(e) shall not apply. This fee shall be in addition to
and shall not replace the license documentation fee provided in Section 4.1(b),
above.  In the event this AGREEMENT is
assigned to a third party in connection with any transaction other than the
sale of all of LICENSEE’s assets to a third party, a percentage of all
consideration received therefor shall be payable to UTMDACC in accordance with
the percentages specified in Section 4.1(e), above.

 

4.2                                 Unless
otherwise provided, all such payments are payable within [*] calendar days
after March 31, June 30, September 30, and December 31 of
each year during the term of this AGREEMENT, at which time LICENSEE will also
deliver to UTMDACC a true and accurate report, giving such particulars of the
business conducted by LICENSEE and its sublicensees, if any exist, during the
preceding three (3) calendar months under this AGREEMENT as necessary for
UTMDACC to account for LICENSEE’s payments hereunder. This report will include
pertinent data, including, but not limited to:

 

(a)                                  the
accounting methodologies used to account for and calculate the items included
in the report and any differences in such accounting methodologies used by
LICENSEE since the previous report; and

 

(b)                                 a
list of LICENSED PRODUCTS produced for the three (3) preceding calendar
months categorized by the technology it relates to under PATENT RIGHTS; and

 

(c)                                  the
total quantities of LICENSED PRODUCTS produced by the category listed in Section 4.2(b);
and

 

10

 

(d)                                 the
total SALES by the category listed in Section 4.2(b); and

 

(e)                                  the
calculation of NET SALES by the category listed in Section 4.2(b); and

 

(f)                                    the
royalties so computed and due UTMDACC by the category listed in Section 4.2(b) and/or
minimum royalties; and

 

(g)                                 all
consideration received from each sublicensee or assignee and payments due
UTMDACC; and

 

(h)           all
other amounts due UTMDACC herein.

 

Simultaneously with the
delivery of each such report, LICENSEE agrees to pay UTMDACC the amount due, if
any, for the period of such report. 
These reports are required even if no payments are due.

 

4.3                                 During
the term of this AGREEMENT and for one (1) year thereafter, LICENSEE
agrees to keep complete and accurate records of all SALES and NET SALES in
sufficient detail to enable the royalties and other payments due hereunder to
be determined. LICENSEE agrees to permit UTMDACC or its representatives, at
UTMDACC’s expense, to periodically examine LICENSEE’s books, ledgers, and
records during regular business hours, and with at least five (5) days’
notice to LICENSEE, for the purpose of and to the extent necessary to verify
any report required under this AGREEMENT. If any amounts due UTMDACC are
determined to have been underpaid in an amount equal to or greater than [*]
percent ([*]%) of the total amount due during the period so examined, then
LICENSEE will pay the cost of the examination plus accrued interest at the lesser
of: (1) the average prime lending rate as published in the Wall Street Journal plus two percent (2%)
during the period being examined; or (2) the highest allowable legal rate.

 

4.4                                 Within
thirty (30) calendar days following each anniversary of the EFFECTIVE DATE,
LICENSEE will deliver to UTMDACC a written progress report as to LICENSEE’s
(and

 

11

 

any sublicensee’s) efforts and accomplishments during
the preceding year in diligently commercializing LICENSED SUBJECT MATTER in the
LICENSED TERRITORY and LICENSEE’s (and sublicensees’) commercialization plans
for the upcoming year.

 

4.5                                 All
amounts payable hereunder by LICENSEE will be paid in United States funds
without deductions for taxes, assessments, fees, or charges of any kind.  Checks are to be made payable to The
University of Texas M. D. Anderson Cancer Center, and sent by United States
mail to Box 297402, Houston, Texas 77297, Attention: Manager, Sponsored Programs
or by wire transfer to:

 

BANK ONE TEXAS

910 TRAVIS

HOUSTON, TEXAS 77002

SWIFT: BONEUS44HOU

 

ABA ROUTING NO:           111000614

ACCOUNT NAME:             UNIV. OF TEXAS M. D. ANDERSON CANCER CENTER

ACCOUNT
NO:                    1586838979

REFERENCE:                         include title and EFFECTIVE DATE of AGREEMENT
and type of payment (e.g., license documentation fee, milestone payment,
royalty [including applicable patent/application identified by MDA reference
number and patent number or application serial number], or maintenance fee,
etc.).

 

4.6                                 No
payments due or royalty rates owed under this AGREEMENT will be reduced as the
result of co-ownership of LICENSED SUBJECT MATTER by BOARD and another party,
including, but not limited to, LICENSEE.

 

V.            SPONSORED RESEARCH AND OPTION

 

5.1                                 If
LICENSEE desires to sponsor research for or related to the LICENSED SUBJECT
MATTER, and particularly where LICENSEE receives payments for sponsored
research pursuant to a sublicense under this AGREEMENT, LICENSEE (a) will
notify UTMDACC in writing of all opportunities to conduct this sponsored
research (including clinical trials, if applicable), (b) solicit research
and/or clinical proposals from

 

12

 

UTMDACC for this purpose,
and (c) will give good faith consideration to funding the proposals at
UTMDACC.

 

5.2                                 For
a period of two (2) years after the EFFECTIVE DATE, LICENSEE shall have a
limited option to negotiate an exclusive, world-wide, royalty-bearing license
to the complex of claim 1 and dependent claims 3-10 (excluding the words “of
Claim 2” in claims 3 and 4) of United States Patent No. 5,434,256 as
follows.  During the two year period
after the EFFECTIVE DATE, either LICENSEE or UTMDACC may initiate the process
of negotiating said license by sending written notice to the other party of its
desire to commence negotiations.  Upon
receipt of said notice, LICENSEE and UTMDACC shall have a period of six (6) months
to negotiate a license.  If the parties
are unable to reach an agreement as to the terms and conditions of said license
during the six (6) month negotiation period, then LICENSEE’s option rights
shall expire and UTMDACC and BOARD shall be free to license the technology to
third parties with no further consideration due to LICENSEE.

 

VI.           PATENTS AND INVENTIONS

 

6.1                                 The
parties do not anticipate filing any patent applications at this time.  If, however, after consultation with LICENSEE
both parties agree that a new patent application should be filed for LICENSED
SUBJECT MATTER, UTMDACC will prepare and file appropriate patent applications,
and LICENSEE will pay the cost of searching, preparing, filing, prosecuting and
maintaining same.  If LICENSEE notifies
UTMDACC that it does not intend to pay the cost of an application, or if
LICENSEE does not respond or make an effort to agree with UTMDACC on the
disposition of rights of the subject invention, then UTMDACC may file such
application at its own expense and LICENSEE’s rights to such

 

13

 

invention under this AGREEMENT shall terminate in
their entirety.  UTMDACC will provide
LICENSEE with a copy of the application for which LICENSEE has paid the cost of
filing, as well as copies of any documents received or filed during prosecution
thereof.  The parties agree that they
share a common legal interest to get valid enforceable patents and that each
party will keep all privileged information received from the other party
pursuant to this Section confidential.

 

VII.         INFRINGEMENT BY THIRD PARTIES

 

7.1                                 LICENSEE,
at its expense, must enforce any PATENT RIGHTS exclusively licensed hereunder
against infringement by third parties and is entitled to retain recovery from
such enforcement.  After reimbursement of
LICENSEE’s reasonable legal costs and expenses related to such recovery,
LICENSEE agrees to pay UTMDACC either:  (a) the
royalty detailed in Section 4.1(c) for any monetary recovery that is
for sales of LICENSED PRODUCTS lost due to the infringement and related
punitive damages; or (b) fifty percent (50%) of reasonable royalties
awarded and related punitive damages in any recovery in which the award is for
reasonable royalties. LICENSEE must notify UTMDACC in writing of any potential
infringement within thirty (30) calendar days of knowledge thereof.  If LICENSEE does not file suit against a substantial
infringer within six (6) months of knowledge thereof, then BOARD or
UTMDACC may, at its sole discretion, enforce any patent licensed hereunder on
behalf of itself and LICENSEE, with UTMDACC retaining all recoveries from such
enforcement, and/or reduce the license granted hereunder to non-exclusive.

 

7.2                                 In
any suit or dispute involving an infringer, the parties agree to cooperate
fully with each other.  At the request
and expense of the party bringing suit, the other party will permit

 

14

 

access during regular business hours, to all relevant
personnel, records, papers, information, samples, specimens, and the like in
its possession.

 

VIII.        PATENT MARKING

 

8.1                                 LICENSEE
agrees that all packaging containing individual LICENSED PRODUCT(S), documentation
therefor, and when possible for actual LICENSED PRODUCT(S) sold by LICENSEE,
AFFILIATES, and/or sublicensees of LICENSEE will be permanently and legibly
marked with the number of any applicable patent(s) licensed hereunder in
accordance with each country’s patent laws, including Title 35, United States
Code.

 

IX.           INDEMNIFICATION AND INSURANCE

 

9.1                           LICENSEE
agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC, its Regents,
officers, employees, students and agents from and against any claims, demands,
or causes of action whatsoever, costs of suit and reasonable attorney’s fees,
including without limitation, those costs arising on account of any injury or
death of persons or damage to property caused by, or arising out of, or
resulting from, the exercise or practice of the rights granted hereunder by
LICENSEE, its officers, its AFFILIATES or their officers, employees, agents or
representatives.

 

9.2                                 In
no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect, special,
consequential or punitive damages (including, without limitation, damages for
loss of profits or expected savings or other economic losses, or for injury to
persons or property) arising out of, or in connection with, this AGREEMENT or
its subject matter, regardless of whether BOARD, SYSTEM or UTMDACC knows or
should know of the possibility of such damages. 
The total aggregate liability of BOARD, SYSTEM and UTMDACC for all
damages of any kind relating to this AGREEMENT or its subject matter shall not
exceed the amounts paid by LICENSEE to BOARD or UTMDACC under this

 

15

 

AGREEMENT during the one (1) year
period preceding the date of the event that gave rise to the liability.  The foregoing exclusions and limitations
shall apply to all claims and actions of any kind, whether based on contract,
tort (including, but not limited to, negligence), or any other grounds.

 

9.3                           Beginning
at the time when any LICENSED SUBJECT MATTER is being distributed or sold
(including for the purpose of obtaining regulatory approvals) by LICENSEE or by
a sublicensee, LICENSEE shall, at its sole cost and expense, procure and
maintain commercial general liability insurance in amounts not less than
$2,000,000 per incident and $2,000,000 annual aggregate, and LICENSEE shall use
reasonable efforts to have the BOARD, SYSTEM, UTMDACC, its Regents, officers,
employees, students and agents named as additional insureds. Such commercial
general liability insurance shall provide: (i) product liability coverage;
(ii) broad form contractual liability coverage for LICENSEE’s
indemnification under this AGREEMENT; and (iii) coverage for litigation
costs. The minimum amounts of insurance coverage required herein shall not be
construed to create a limit of LICENSEE’s liability with respect to its
indemnification under this AGREEMENT.

 

9.4                                 LICENSEE
shall provide UTMDACC with written evidence of such insurance within thirty
(30) days of its procurement. 
Additionally, LICENSEE shall provide UTMDACC with written notice of at least
fifteen (15) days prior to the cancellation, non-renewal or material change in
such insurance.

 

9.5                                 LICENSEE
shall maintain such commercial general liability insurance beyond the
expiration or termination of this AGREEMENT during: (i) the period that any
LICENSED SUBJECT MATTER developed pursuant to this AGREEMENT is being

 

16

 

commercially distributed
or sold by LICENSEE or by a sublicensee or agent of LICENSEE; and (ii) the
five (5) year period immediately after such period.

 

X.            USE
OF BOARD AND UTMDACC’S NAME

 

10.1                           LICENSEE
will not use the name of (or the name of any employee of) UTMDACC, SYSTEM or
BOARD in any advertising, promotional or sales literature, on its Web site, or
for the purpose of raising capital without the advance express written consent
of BOARD secured through:

 

M. D. Anderson Services
Corporation

7505 S. Main, Suite 500,
Unit 0525

Houston, TX 77030

ATTENTION:  Natalie Wright

Email:  nwright@mdanderson.org

 

Notwithstanding the above, LICENSEE may use the name
of (or name of employee of) UTMDACC, SYSTEM or BOARD in routine business
correspondence, or as needed in appropriate regulatory submissions without
express written consent.

 

XI.           CONFIDENTIAL INFORMATION AND PUBLICATION

 

11.1                           UTMDACC
and LICENSEE each agree that all information contained in documents marked “confidential”
and forwarded to one by the other (i) are to be received in strict
confidence, (ii) are to be used only for the purposes of this AGREEMENT,
and (iii) will not be disclosed by the recipient party (except as required
by law or court order), its agents or employees without the prior written
consent of the other party, except to the extent that the recipient party can
establish by competent written proof that such information:

 

(a)                                  was
in the public domain at the time of disclosure; or

 

(b)                                 later
became part of the public domain through no act or omission of the recipient
party, its employees, agents, successors or assigns; or

 

17

 

(c)                                  was
lawfully disclosed to the recipient party by a third party having the right to
disclose it; or

 

(d)                                 was
already known by the recipient party at the time of disclosure; or

 

(e)                                  was
independently developed by the recipient without use of the other party’s
confidential information; or

 

(f)                                    is
required by law or regulation to be disclosed.

 

11.2                           Each
party’s obligation of confidence hereunder will be fulfilled by using at least
the same degree of care with the other party’s confidential information as it
uses to protect its own confidential information, but always at least a
reasonable degree of care. This obligation will exist while this AGREEMENT is
in force and for a period of three (3) years thereafter.

 

11.3                           UTMDACC
reserves the right to publish the general scientific findings from research
related to LICENSED SUBJECT MATTER, with due regard to the protection of
LICENSEE’s confidential information. 
UTMDACC will submit the manuscript of any proposed publication to
LICENSEE at least forty-five (45) calendar days before publication, and
LICENSEE shall have the right to review and comment upon the publication in
order to protect LICENSEE’s confidential information. Upon LICENSEE’s request,
publication may be delayed up to sixty (60) additional calendar days to enable
LICENSEE to secure adequate intellectual property protection of LICENSEE’s
confidential information that would otherwise be affected by the publication.

 

XII.         ASSIGNMENT

 

12.1                     Notwithstanding
any other provision herein to the contrary, except in connection with the sale
of all of LICENSEE’s assets to a third party, this AGREEMENT may not be

 

18

 

assigned by LICENSEE
without the prior written consent of UTMDACC, which will not be unreasonably
withheld.

 

XIII.        TERM
AND TERMINATION

 

13.1                           Subject
to Sections 13.4, 13.5 hereinbelow, the term of this AGREEMENT is from the
EFFECTIVE DATE to the full end of the term or terms for which PATENT RIGHTS
have not expired, or if only TECHNOLOGY RIGHTS are licensed and no PATENT
RIGHTS are applicable, for a term of fifteen (15) years.

 

13.2                           Any
time after two and on half (2.5) years from the EFFECTIVE DATE, BOARD or
UTMDACC have the right to terminate this license in any national political
jurisdiction within the LICENSED TERRITORY if LICENSEE, within ninety (90)
calendar days after receiving written notice from UTMDACC of the intended
termination, fails to provide written evidence satisfactory to UTMDACC that
LICENSEE or its sublicensee(s) has commercialized or is actively and
effectively attempting to commercialize a licensed invention in such
jurisdiction(s).  The following
definitions apply to Section 13.2: (a) “commercialize” means having
SALES in such jurisdiction; (b) ”active attempts to commercialize” means
having an effective, ongoing and active research, development, manufacturing,
marketing or sales program as appropriate, directed toward obtaining regulatory
approval, and/or production and/or SALES in any jurisdiction, and has provided
plans acceptable to UTMDACC, in its sole discretion, to commercialize licensed
inventions in the jurisdiction(s) that UTMDACC intends to terminate.

 

13.3                           In
addition to the foregoing obligations to commercialize, LICENSEE must commence
a Phase I Clinical Trial for a LICENSED PRODUCT within two and one half (2.5)
years from the EFFECTIVE DATE.  If
LICENSEE fails to timely commence such Trial, BOARD or UTMDACC have the right
to terminate this license if LICENSEE, within

 

19

 

ninety (90) calendar days after receiving written
notice from UTMDACC of the intended termination, fails to provide written
evidence satisfactory to UTMDACC that a Phase I Clinical Trial for a LICENSED
PRODUCT has commenced.  As used herein, a
Phase I Clinical Trial is “commenced” upon first dosing of a patient with a
LICENSED PRODUCT in connection with said Trial.

 

13.4                           Subject
to any rights herein which survive termination, this AGREEMENT will earlier
terminate in its entirety:

 

(a)                                  automatically,
if LICENSEE becomes bankrupt or insolvent and/or if the business of LICENSEE
shall be placed in the hands of a receiver, assignee, or trustee, whether by
voluntary act of LICENSEE or otherwise; or

 

(b)                                 upon
thirty (30) calendar days written notice from UTMDACC, if LICENSEE breaches or
defaults on the payment or report obligations of ARTICLE IV, or use of
name obligations of ARTICLE X, unless, before the end of the such thirty
(30)-calendar day notice period, LICENSEE has cured the default or breach to
UTMDACC’s satisfaction, and so notifies UTMDACC, stating the manner of the
cure; or

 

(c)                                  upon
ninety (90) calendar days written notice from UTMDACC if LICENSEE breaches or
defaults on any other obligation under this AGREEMENT, unless, before the end
of the such ninety (90) calendar-day notice period, LICENSEE has cured the
default or breach to UTMDACC’s satisfaction and so notifies UTMDACC, stating
the manner of the cure; or

 

(d)                                 at
any time by mutual written agreement between LICENSEE and UTMDACC upon one
hundred eighty (180) calendar days written notice to all parties and subject to
any terms herein which survive termination; or

 

20

 

(e)                                  if
Sections 13.2 or 13.3 is invoked; or

 

(f)                                    if
LICENSEE has defaulted or been late on its payment obligations pursuant to the
terms of this AGREEMENT on any two (2) occasions in a twelve (12) month
period.

 

13.5         Upon
termination of this AGREEMENT:

 

(a)                                  nothing
herein will be construed to release either party of any obligation maturing
prior to the effective date of the termination; and

 

(b)                                 The
parties covenant and agree to be bound by the provisions of Articles IX
(Indemnification and Insurance), X (Use of Board and UTMDACC’s Name) and XI
(Confidential Information and Publication) of this AGREEMENT; and

 

(c)                                  LICENSEE
may, after the effective date of the termination, sell all LICENSED PRODUCTS
and parts therefor that it has on hand at the date of termination, if LICENSEE
pays the earned royalty thereon and any other amounts due pursuant to Article IV
of this AGREEMENT; and

 

(d)                                 LICENSEE
grants to BOARD and UTMDACC a nonexclusive royalty bearing license with the
right to sublicense others with respect to improvements made by LICENSEE
(including improvements licensed by LICENSEE from third parties) in the
LICENSED SUBJECT MATTER.  LICENSEE and
UTMDACC agree to negotiate in good faith the royalty rate for the nonexclusive
license. BOARD’s and UTMDACC’s right to sublicense others hereunder is solely
for the purpose of permitting others to develop and commercialize the entire
technology package.

 

XIV.        WARRANTY: SUPERIOR-RIGHTS

 

14.1                           Except
for the rights, if any, of the Government of the United States of America as
set forth below, BOARD represents and warrants its belief that (a) it is
the owner of the

 

21

 

entire right, title, and
interest in and to LICENSED SUBJECT MATTER, (b) it has the sole right to
grant licenses thereunder, and (c) it has not knowingly granted licenses
thereunder to any other entity that would restrict rights granted hereunder
except as stated herein.

 

14.2                           LICENSEE
understands that the LICENSED SUBJECT MATTER may have been developed under a
funding agreement with the Government of the United States of America and, if
so, that the Government may have certain rights relative thereto.  This AGREEMENT is explicitly made subject to
the Government’s rights under any such agreement and any applicable law or
regulation, including P.L. 96-517 as amended by P.L. 98-620.  To the extent that there is a conflict
between any such agreement, applicable law or regulation and this AGREEMENT,
the terms of such Government agreement, applicable law or regulation shall
prevail.

 

14.3                           LICENSEE
understands and agrees that BOARD and UTMDACC, by this AGREEMENT, make no
representation as to the operability or fitness for any use, safety, efficacy,
approvability by regulatory authorities, time and cost of development,
patentability, and/or breadth of the LICENSED SUBJECT MATTER. BOARD and
UTMDACC, by this AGREEMENT, also make no representation as to whether any
patent covered by PATENT RIGHTS is valid or as to whether there are any patents
now held, or which will be held, by others or by BOARD or UTMDACC in the
LICENSED FIELD, nor does BOARD and UTMDACC make any representation that the
inventions contained in PATENT RIGHTS do not infringe any other patents now
held or that will be held by others or by BOARD.

 

14.4                           LICENSEE,
by execution hereof, acknowledges, covenants and agrees that LICENSEE has not
been induced in any way by BOARD, SYSTEM, UTMDACC or employees

 

22

 

thereof to enter into this AGREEMENT, and further
warrants and represents that (a) LICENSEE has conducted sufficient due
diligence with respect to all items and issues pertaining to this AGREEMENT;
and (b) LICENSEE has adequate knowledge and expertise, or has used
knowledgeable and expert consultants, to adequately conduct such due diligence,
and agrees to accept all risks inherent herein.

 

XV.         GENERAL

 

15.1                           This
AGREEMENT constitutes the entire and only agreement between the parties for
LICENSED SUBJECT MATTER and all other prior negotiations, representations,
agreements and understandings are superseded hereby.  No agreements altering or supplementing the
terms hereof will be made except by a written document signed by both parties.

 

15.2                           Any
notice required by this AGREEMENT must be given by prepaid, first class,
certified mail, return receipt requested, and addressed in the case of UTMDACC
to:

 

The University of Texas
M. D. Anderson Cancer Center

Office of Technology Commercialization

7515 S. Main, Suite 490, Unit 0510

Houston, Texas 77030

ATTENTION: William J. Doty

 

with copy to BOARD:

 

BOARD OF REGENTS

The University of Texas System

201 West Seventh Street

Austin, Texas 78701

ATTENTION: Office of General Counsel

 

or in the case of
LICENSEE to:

 

ChemGenex Pharmaceuticals Limited

1 Pigdons Road

Waurn Ponds, Victoria, 3217

Australia

ATTENTION: Rick Merrigan

 

23

 

or other addresses as may be given from time to time
under the terms of this notice provision.

 

15.3                           LICENSEE
must comply with all applicable federal, state and local laws and regulations
in connection with its activities pursuant to this AGREEMENT.

 

15.4                           This
AGREEMENT will be construed and enforced in accordance with the laws of the
United States of America and of the State of Texas, without regard to its
conflict of law provisions.  The Texas
State Courts of Harris County, Texas (or, if there is exclusive federal
jurisdiction, the United States District Court for the Southern District of
Texas) shall have exclusive jurisdiction and venue over any dispute arising out
of this AGREEMENT, and LICENSEE consents to the jurisdiction of such courts; however,
nothing herein shall be deemed as a waiver by BOARD, SYSTEM or UTMDACC of its
sovereign immunity.

 

15.5                           Any
dispute or controversy arising out of or relating to this AGREEMENT, its
construction or its actual or alleged breach will be decided by mediation.  If the mediation does not result in a
resolution of such dispute or controversy, it will be finally decided by an
appropriate method of alternate dispute resolution, including without
limitation, arbitration, conducted in the city of Houston, Harris County,
Texas, in accordance with the applicable, then-current procedures of the
American Arbitration Association.  The
arbitration panel will include members knowledgeable in the evaluation of the
LICENSED SUBJECT MATTER.  Judgment upon
the award rendered may be entered in the highest court or forum having
jurisdiction, state or federal.  The
provisions of this Section 15.5 will not apply to decisions on the
validity of patent claims or to any dispute or controversy as to which any
treaty or law prohibits such arbitration. 
The decision of

 

24

 

the arbitration must be
sanctioned by a court of law having jurisdiction to be binding upon and
enforceable by the parties.

 

15.6                           Failure
of LICENSEE, BOARD or UTMDACC to enforce a right under this AGREEMENT will not
act as a waiver of right or the ability to later assert that right relative to
the particular situation involved.

 

15.7                           Headings
included herein are for convenience only and will not be used to construe this
AGREEMENT.

 

15.8                           If any
part of this AGREEMENT is for any reason found to be unenforceable, all other
parts nevertheless will remain enforceable.

 

25

 

IN WITNESS WHEREOF, the parties hereto
have caused their duly authorized representatives to execute this AGREEMENT.

 

 

	
  BOARD OF REGENTS OF THE

  UNIVERSITY OF TEXAS SYSTEM

  	
  CHEMGENEX
  PHARMACEUTICALS

  LIMITED

  
	
   

  	
   

  
	
  By

  	
   

  	
   

  	
  By

  	
   

  	
   

  
	
   

  	
  John Mendelsohn, M.D.

  	
  Name:

  	
   

  	
   

  
	
   

  	
  President

  	
  Title:

  	
   

  	
   

  
	
   

  	
  The University of Texas

  	
   

  
	
   

  	
  M. D. Anderson Cancer
  Center

  	
   

  
	
  Date:

  	
   

  	
   

  	
  Date:

  	
   

  	
   

  
	
   

  	
   

  
	
  THE UNIVERSITY OF TEXAS

  	
   

  
	
  M. D. ANDERSON CANCER
  CENTER

  	
   

  
	
   

  	
   

  
	
  By

  	
   

  	
   

  	
   

  
	
   

  	
  Leon Leach

  	
   

  
	
   

  	
  Executive Vice
  President

  	
   

  
	
   

  	
  The University of Texas

  	
   

  
	
   

  	
  M. D. Anderson Cancer
  Center

  	
   

  
	
  Date:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
  Approved as to Content:

  	
   

  
	
   

  	
   

  
	
  By

  	
   

  	
   

  	
   

  
	
   

  	
  William J. Doty

  	
   

  
	
   

  	
  Managing Director,
  Technology

  	
   

  
	
   

  	
  Commercialization

  	
   

  
	
   

  	
  M. D. Anderson Cancer
  Center

  	
   

  
	
  Date:

  	
   

  	
   

  	
   

  	
   

  	
   

  
															

 

26

 

EXHIBIT I

 

United States Patent No. 5,434,256,
entitled, “Diamine Platinum Complexes as Anti-Tumor Agents,” Claims 2-11,
excluding the words of “Claim 1 or” in Claims 3 and 4 (MDA88-020),
Inventors:  Abdul R. Khokhar and Zahid H.
Siddik.  PATENT RIGHTS do not include the
complex of Claim 1, compositions comprising the complex of claim 1, or methods
of making or using the complex of Claim 1, as set forth in United States Patent
No. 5,434,256.

 

27Exhibit 4.2(u)

 

VOTING RIGHTS DEED

	
  Made on the
  21st day of June 2004

  	
   

  	
  2004

  

 

	
  BETWEEN

  	
  DENNIS BROWN of
  [                 ]

   

  (‘Grantor’)

  
	
   

  	
   

  
	
  AND

  	
  CHARTER PACIFIC CORPORATION LIMITED ACN 003
  344 287 of Level 18, 50 Cavill
  Avenue, Surfers Paradise, Queensland, 4217

   

   (‘Grantee’)

  

 

RECITALS

 

A.                                  The
Grantor is the holder of
14,398,297 Shares.

 

B.                                    The Grantee is the holder of 19,265,187 Shares.

 

C.                                    The Grantor has agreed to appoint the Grantee as its proxy in
respect of the Proxy Shares upon the terms set out in this Deed.

 

AGREEMENT

 

1.                                      DEFINITIONS

 

In this Deed, except to the extent that the
context otherwise requires:

 

(a)                                 ‘AGT Biosciences’ means AGT
Biosciences Limited ACN 000 248 304;

 

(b)                                ‘Commencement
Date’
means the date of this Deed;

 

(c)                                 ‘Proxy Shares’ means the number of
Shares represented by A in the following formula:

 

A = ((25/100 x B) + 1) — C

 

B = the total number of issued Shares from
time to time

 

C = the number of Shares beneficially owned
by the Grantee from time to time.

 

(d)                                ‘Share’ means an ordinary
share in the capital of AGT Biosciences;

 

(e)                                 ‘Termination
Date’
means that date 2 years after the date of this Deed;

 

2.                                      INTERPRETATION

 

In this Deed, except to the extent that the
context otherwise requires:

 

(a)                                 words importing the
singular include the plural and vice versa and words importing a gender include
other genders;

 

(b)                                a reference to an Act
of Parliament or Code or section or schedule of that Act or Code shall be read
as if the words ‘and any statutory modification or re-enactment of it or
substitution of if were added
to the reference and includes all statutory instruments issued from time to
time under that Act or Code;

 

 

(c)                                 where a word or
phrase is given a particular meaning, other parts of speech or grammatical
forms of that word or phrase have corresponding meanings;

 

(d)                                references to a
recital, clause, schedule or annexure shall be construed as references to a
recital or clause of or schedule or annexure to this Deed and references to
this Deed include any of its schedules and any annexures;

 

(e)                                 where a party
comprises two or more persons an agreement or obligation to be performed or
observed by that party binds those persons jointly and severally and a
reference to that party includes a reference to any one or more of those persons;

 

(f)                                   expressions and terms
expressly used in this Deed which are defined in the Corporations Act as at the
date of this Deed have the same meanings as have been ascribed to them in the
Corporations Act as at the date of this Deed;

 

(g)                                a reference to a
party to this Deed or any other document or agreement includes its successors
and permitted assigns;

 

(h)                                a reference to a
party shall be construed as a reference to a party to this Deed;

 

(i)                                    a reference to a
document or agreement including this Deed includes a reference to that document
or agreement as amended, novated, supplemented, varied or replaced from time to
time;

 

(j)                                    in the interpretation
of this Deed, headings shall be disregarded;

 

(k)                                 references to ‘$A’, ‘dollar’,
‘$’ and
to any amount not otherwise designated shall be construed as references to
Australian currency;

 

(l)                                    a reference to
writing includes typewriting, printing, lithography, photography and any other
mode of representing or reproducing words in a permanent and visible form; and

 

(m)                              if any day appointed
or specified by this Deed for the payment of any money or the doing of any act,
matter or thing falls on a Saturday, Sunday or a day on which banks (as defined
in the Banking Act 1959 of the Commonwealth) are not open for business in
Brisbane (a ‘Non Business Day’), the day so appointed or specified shall be
deemed to be the next day which
is not a
Non Business Day.

 

3.                                      STANDING PROXY

 

The Grantor unconditionally and irrevocably
appoints the Grantee as its standing proxy for the Proxy Shares to attend and
vote at its discretion at any meeting or meetings of AGT Biosciences until
termination of this Deed in respect of all matters put before shareholders and
agrees not to exercise or attempt to exercise or grant any rights in respect of
the voting rights attached to the Proxy Shares until termination of this Deed.

 

4.                                      TERM

 

This Deed commences on the Commencement Date
and terminates on the Termination Date.

 

5.                                      TERMINATION

 

This Deed will automatically lapse when the
number of Shares beneficially owned by the Grantee is less than 10% of the
total number of Shares on issue from time to time.

 

6.                                      STAMP DUTY AND
COSTS

 

Any stamp duty payable on this Deed or
relating to the transactions evidenced by it is to be borne by and paid by the
Grantee. Each party will bear their own professional costs of and incidental to
the preparation and execution of this Deed.

 

2

 

7.                                      COUNTERPARTS

 

This Deed may be executed in any number of
counterparts and all such counterparts taken together shall be deemed to
constitute one instrument.

 

8.                                      ENTIRE AGREEMENT

 

This Deed:

 

(a)                                 constitutes the
entire agreement of the parties as to its subject matter and supersedes and
cancels all prior arrangements, understandings and negotiations in connection
with it; and

 

(b)                                may only be altered
in writing signed by all parties.

 

9.                                      FURTHER ASSURANCES

 

9.1                                Each party shall do
everything necessary or desirable to give full effect to this Deed, and shall
refrain from doing anything which might prevent full effect being given to this
Deed.

 

9.2                                Without limiting
clause 10.1 the Grantor authorises the Grantee to execute on its behalf as its
duly authorised agent any documentation that may be required by AGT Biosciences
in relation to the voting rights of the Proxy Shares.

 

10.                                AMENDMENTS IN
WRITING

 

No amendment to this Deed has any force
unless it is in writing and signed by the all of the parties to this Deed.

 

11.                                GOVERNING LAW

 

11.1                          This Deed is governed
by the laws of Queensland and the Commonwealth of Australia.

 

12.                                FACSIMILE

 

The parties agree that an executed facsimile
copy of this Deed will be binding on all parties.

 

EXECUTED as a deed

 

 

	
  EXECUTED IN ACCORDANCE WITH

  	
  )

  	
   

  	
   

  	
   

  
	
  SECTION 127 OF THE CORPORATIONS ACT

  	
   

  	
   

  	
   

  	
   

  
	
  BY CHARTER
  PACIFIC CORPORATION 

  	
  )

  	
   

  	
   

  	
   

  
	
  LIMITED ACN 003 344 287  in the presence of:

  	
  )

  	
   

  	
   

  	
   

  
	
   

  	
  )

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Ù

  	
  Director

  	
   

  	
   

  	
  Ù

  	
  Director/Secretary

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Ù

  	
  Full name of director

  	
   

  	
   

  	
  Ù

  	
  Full name of
  director/secretary

  	
   

  
								

 

3

 

	
  SIGNED SEALED AND DELIVERED

  	
  )

  	
   

  	
   

  
	
  by DENNIS BROWN in the presence
  of:

  	
  )

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Ù

  	
  Signature of DENNIS
  BROWN

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Ù

  	
  Signature of witness

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Ù

  	
  Name of witness (print)

  	
   

  	
   

  	
   

  	
   

  

 

4

 

 

 

 

VOTING RIGHTS DEED

 

 

 

DENNIS BROWN 

 

and

 

CHARTER PACIFIC CORPORATION LIMITED ACN 003
344 287

 

 

Level 12  
Central Plaza Two

66 Eagle Street   Brisbane

GPO Box 1855  
Brisbane  Qld  4001

Telephone 
(07) 3233 8888   Fax  (07) 3229 9949

Email 
info@mccullough.com.au

http://www.mccullough.com.au/

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]